retatrutide gip glp-1 glucagon receptor agonist Retatrutide, a GIP, and agonist, for people with type 2 diabetes: a randomised, double-blind, placebo and active-controlled, parallel-group, phase 2 trial conducted in the USA Science Behind GLP 1 GIP

Mounjaro (tirzepatide) is a dual agonist targeting GLP-1 and GIP, producing up to 22.5% weight loss

Understanding these trials, what they measure, and what the results mean, is essential for anyone tracking this compound

compounding pharmacy, ideally a 503A or 503B facility following recognized quality and sterility standards, the risk profile is meaningfully different from purchasing through an unverified source

In this review, we discuss the mechanistic and clinical synergies that make the combined use of GLP-1RAs and SGLT2is appealing in patients with T2DM

With years of supply shortages, prices for GLP-1s for weight loss are often high to begin with and are sparingly covered by health insurers